| Observation time (person‐year) | No. event | Incidence rate (95%CI) (per 100‐person year) | HR (95%CI) | HR* (95%CI) | HR† (95%CI) | HR†‡ (95%CI) | |
|---|---|---|---|---|---|---|---|
| TTR > 45% | 5735.75 | 290 | 5.06 (4.49‐5.67) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| TTR ≤ 45% | 1736.54 | 144 | 8.29 (6.99‐9.76) | 1.64 (1.34‐2.01) | 1.66 (1.35‐2.03) | 1.63 (1.32‐2) | 1.49 (1.17‐1.9) |
| TTR > 60% | 4564.35 | 213 | 4.67 (4.06‐5.34) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| TTR ≤ 60% | 2907.94 | 221 | 7.6 (6.63‐8.67) | 1.6 (1.28‐2) | 1.59 (1.27‐2) | 1.55 (1.23‐1.95) | 1.55 (1.23‐1.95) |
| TTR > 70% | 3656.69 | 169 | 4.62 (3.95‐5.37) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| TTR ≤ 70% | 3815.61 | 265 | 6.95 (6.13‐7.83) | 1.52 (1.21‐1.92) | 1.51 (1.19‐1.91) | 1.47 (1.16‐1.87) | 1.47 (1.16‐1.87) |
*Adjusted for age, sex, and anticoagulation clinics.
†Adjusted for age, sex, anticoagulation clinics, and comorbidities (chronic obstructive pulmonary disease, asthma, other chronic lung diseases, congestive heart failure, hypertension, myocardial infarction history, abnormal liver function, gastroesophageal reflux disease, peptic ulcer disease, abnormal renal function, anemia, coagulopathy, diabetes mellitus, thyroid disease, autoimmune disease, systemic connective tissue disorders, stroke/TIA history, Alzheimer's disease, Parkinson's disease, peripheral artery disease, deep vein thrombosis, pulmonary embolism, arterial embolism and thrombosis, major bleeding history, malignant tumor).
‡Restricted to patients who had a baseline CHA2DS2‐VASc ≥ 2.
Abbreviations: DOAC, direct oral anticoagulants; OAC, oral anticoagulants; TTR, time in therapeutic range; VKA, Vitamin K antagonists; HR, hazard ratio; CI, confidence interval.